Evidence map›Paper›PMID 40853888›Full record

ArticleThe American journal of case reports2025

Rapid Progression of Primary Hepatic Neuroendocrine Carcinoma: A Case Report Demonstrating Drastic Oncological Behavior.

Rina Kobayashi, Tomohide Hori, Makoto Yamawaki, Shigeki Nakayama, Satoru Umegae, Takao Iwanaga, Ryutaro Nishikawa, Takahiro Shimoyama, Sakurako Suzuki, Shinichiro Atsumi and 10 more

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rina KobayashiDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Tomohide HoriDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.ORCID 0000-0002-8282-4403
Makoto YamawakiDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Shigeki NakayamaDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Satoru UmegaeDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Takao IwanagaDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Ryutaro NishikawaDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Takahiro ShimoyamaDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Sakurako SuzukiDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Shinichiro AtsumiDepartment of Pathology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Hiroshi HasegawaDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Shigehito NakashimaDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Kunihiro HiguchiDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Kentaro OnishiDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Ryotaro SakaguchiDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Shoichi MoritaDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Haruka MiyaoDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Saki AotaDepartment of Gastroenterology, Yokkaichi Hadu Medical Center, Yokkaichi, Mie, Japan.
Hikaru OhtaniDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
Takayuki YamamotoDepartment of Surgery, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Primary hepatic neuroendocrine neoplasms (PHNENs), including primary hepatic neuroendocrine carcinoma (PHNEC), are extremely rare. PHNENs typically exhibit slow growth, although mixed neuroendocrine-non-neuroendocrine neoplasms have poor prognoses. PHNENs are also challenging to diagnose. CASE REPORT A 73-year-old man underwent plain computed tomography (CT), which incidentally detected a 42-mm solitary hepatic tumor. Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) were elevated at 138 mAU/mL. Thirteen days later, magnetic resonance imaging (MRI) revealed an enlarged hepatic tumor with tumor thromboses extending into the hepatic and portal veins. No early-phase enhancement was observed. At 18 days, Doppler ultrasound and dynamic CT evaluated the tumor as hypovascular, and a newly swollen solitary lymph node appeared. At 39 days, positron emission tomography (PET)/CT revealed strong uptake in the primary liver tumor and metastatic lymph nodes, with additional distant lymph node metastases emerging. At 49 days, a metastatic cervical lymph node was surgically resected. At 61 days, PHNEC was definitively diagnosed based on histopathological and immunohistochemical assessments. The Ki-67 labeling index was >90%. At 67 days, he was hospitalized to begin chemotherapy, but CT revealed end-stage disease. Palliative treatment was required, and the patient died of cancer 82 days after the initial diagnosis. CONCLUSIONS We have presented a thought-provoking case of PHNEC with rapid oncological progression. To clarify clinical implications (eg, atypical imaging features and diagnostic pitfalls), detailed imaging findings are provided. We anticipate that this case will be informative for clinicians in this field.

Indexed as

Carcinoma, NeuroendocrineLiver NeoplasmsAgedDisease ProgressionFatal OutcomeHumansMagnetic Resonance ImagingMalePositron Emission Tomography Computed TomographyTomography, X-Ray Computed

Identifiers

PMID40853888
PMCPMC12396091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.